Considerations regarding maintenance therapy for acute myeloid leukemia in remission

By sjmartinez • February 13, 2024

Schiller GJ, Kustanovich V. Considerations regarding maintenance therapy for acute myeloid leukemia in remission. Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):15-20. doi: 10.1080/14737140.2024.2306164. Epub 2024 Feb 12. PMID: 38230741.

Tags: allogeneic, AML, Hematology/Oncology, maintenance, Publications, remission, targets, therapy, transplantation

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]